BransonBMHandsfieldHHLampeMA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.
3.
MartinEGSchackmanBR. Updating the HIV-testing guidelines—a modest change with major consequences. N Engl J Med. 2013;368(10):884–6.
4.
MarksGCrepazNSenterfittJWJanssenRS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446–53.
5.
KitahataMMGangeSJAbrahamAG. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.
6.
CohenMSChenYQMcCauleyM. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
7.
PaltielADWeinsteinMCKimmelAD. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.
8.
WalenskyRPWeinsteinMCKimmelAD. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005;118(3):292–300.
9.
SandersGDBayoumiAMSundaramV. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.
10.
SandersGDAnayaHDAschS. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2008;25(6):556–63.
11.
SandersGDBayoumiAMHolodniyMOwensDK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889–903.
12.
WalenskyRPPaltielADLosinaE. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392–400.
13.
SchackmanBRMetschLRColfaxGN. The cost-effectiveness of on-site rapid HIV testing in substance abuse treatment: results of the CTN 0032 randomized trial. Drug Alcohol Depend. 2013;128(1–2):90–7.
14.
ChouRSelphSDanaT. Screening for HIV: systematic review to update the 2005 US Preventive Services Task Force recommendation. Ann Intern Med. 2012;157(10):706–18.
15.
PaltielADWalenskyRPSchackmanBR. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797–806.
16.
FarnhamPGSansomSLHutchinsonAB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making. 2012;32(3):459–69.
17.
JohnstonKMLevyARLimaVD. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS. 2010;24(12):1929–35.
18.
SchackmanBRGeboKAWalenskyRP. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–7.
19.
LosinaESchackmanBRSadownikSN. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49(10):1570–8.
20.
LosinaELinasBHyleE. Projecting 10-year, 20-year, and lifetime risks of cardiovascular disease in HIV+ individuals in the US: competing risks and premature aging. 20th Conference on Retroviruses and Opportunistic Infections; March 3–6, 2013; Atlanta, Georgia.
21.
GardnerEMMcLeesMPSteinerJFDel RioCBurmanWJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
22.
Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment—United States. Morb Mortal Wkly Rep. 2011;60(47):1618-23.
23.
MontanerJNosykBColleyG. The evolution of the cascade of HIV care: British Columbia, Canada 1996-2010. 20th Conference on Retroviruses and Opportunistic Infections; March 3–6, 2013; Atlanta, Georgia.
